布地格福气雾吸入剂治疗慢性阻塞性肺疾病合并支气管哮喘患者的临床效果及安全性观察

Evaluate the efficacy and safety of budesonide glycopyrronium bromide and formoterol fumarate inhalation aerosol(GFF MID)for treatment of patients with chronic obstructive pulmonary disease and bronchial asthma

目的观察布地格福气雾吸入剂治疗慢性阻塞性肺疾病合并支气管哮喘患者的临床效果及安全性。方法分析首都医科大学石景山教学医院呼吸科于2020年3月-2021年3月期间接受布地格福气雾吸入剂治疗的50例慢性阻塞性肺疾病合并支气管哮喘患者的临床特征,治疗疗程为3个月,比较治疗前及治疗后患者的慢性阻塞性肺疾病症状控制评分(CAT)、哮喘控制评分(ACT)、圣乔治呼吸问卷(SGRQ)评分、FEV1、FEV1占预值%(FEV1%pred)、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC%)、PEF占预计值%(PEF%pred);呼出气一氧化氮(FeNO)、急性发作次数变化。结果经过3个月治疗后,慢性阻塞性肺疾病合并支气管哮喘患者CAT评分从(22.75±1.66)分降至(16.63±2.72)分,ACT评分从(16.33±0.65)分升至(22.35±0.53)分,SGRQ评分从(46.03±6.04)分降至(36.59±4.56)分,差异均有统计学意义(P<0.05),FEV1由(1.40±0.42)L升至(1.80±0.40)L、FEV1%pred由(48.33±6.72)%升至(74.30±7.71)%、FEV1/FVC%由(56.43±8.01)%升至(68.52±8.03)%、PEF%pred由(68.73±3.61)%升至(83.58±3.75)%,差异均有统计学意义(P<0.05);FeNO从(52.53±5.62)ppb降至(25.65±4.81)ppb,差异具有统计学意义(P<0.001);急性发作次数从(2.01±0.22)次/3个月减至(0.52±0.17)次/3个月(P<0.001)。治疗期间有1例患者出现咽喉部不适,1例患者出现声音嘶哑,不良反应发生率为4%。结论布地格福气雾吸入剂治疗慢性阻塞性肺疾病合并支气管哮喘患者可以改善症状、提升肺功能、降低FeNO、减少急性发作次数,效果明确且安全性高。

Objective To evaluate the efficacy and safety of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol(GFF MID)for treatment of patients with chronic obstructive pulmonary disease and bronchial asthma.Methods Clinical data of 50 cases of patients with chronic obstructive pulmonary disease and bronchial asthma were collected from March 2020 to March 2021 of Respiratory Medicine,Beijing Shijingshan Hospital.Clinical characteristics of patients with chronic obstructive pulmonary disease and bronchial asthma with GFF MID treatment were summarized,while results of CAT score,ACT score,SGRQ,FEV1,FEV1%pred,FEV1/FVC%,PEF%pred,FeNO,acute attack frequency before and after GFF MID treatment were compared in this study.Adverse reactions were also recorded.Results 50 patients with chronic obstructive pulmonary disease and bronchial asthma with positive allergen test results were enrolled in this study.CAT from(22.75±1.66)to(16.63±2.72),ACT from(16.33±0.65)to(22.35±0.53),SGRQ from(46.03±6.04)to(36.59±4.56),FEV1 increased from(1.40±0.42)L to(1.80±0.40)L,FEV1%pred increased from(48.33±6.72)%to(74.30±7.71)%,FEV1/FVC%increased from(56.43±8.01)%to(68.52±8.03)%,PEF%pred increased from(68.73±3.61)%to(83.58±3.75)%,respectively(P<0.05);whereas FeNO decreased from(52.53±5.62)ppb to(25.65±4.81)ppb(P<0.001),after GFF MID treatment.Acute attack frequency decreased from(2.01±0.22)to(0.52±0.17)per three months(P<0.001),adverse reactions occurred in patients(4%),throat discomfort in one case,and hoarseness in another case.Conclusions Patients with chronic obstructive pulmonary disease and bronchial asthma can be controlled by GFF MID treatment,showed by decreases of acute attack frequencies and improvement of pulmonary function.Its efficacy and safety have been well-documented.